Evotec SE (EVOTF) EBT Margin (2020 - 2025)
Evotec SE's (EVOTF) quarterly EBT Margin came in at 34208.36% in Q4 2025, up 5340416.0% year-on-year from N/an in Q4 2024, and down 130400.58% quarter-over-quarter from 26.21% in Q3 2025.
Evotec SE (EVOTF) EBT Margin (2020 - 2025) Analysis & Trends
Evotec SE has disclosed EBT Margin across 6 years of filings, most recently posting 34208.36% for Q4 2025.
- EBT Margin for Q4 2025 came in at 34208.36%, up 5340416.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 33272.38% (down 1027278.0% YoY), and the FY2025 annual result was 11.01%, up 2433838297.0% from the prior year.
- EBT Margin came in at 34208.36% for Q4 2025 at Evotec SE, down from 26.21% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 54929.35% in Q4 2021 to a low of 87612.52% in Q4 2024.
- The 5-year median for EBT Margin is 14.13% (2022), against an average of 7390.06%.
- Across the five-year window, EBT Margin slumped 509967574 bps in 2021 and jumped 5340416 bps in 2025, its largest moves.
- Evotec SE's EBT Margin stood at 54929.35% in 2021, then slumped by 155 bps to 30169.5% in 2022, then surged by 54 bps to 13882.89% in 2023, then slumped by 531 bps to 87612.52% in 2024, then surged by 61 bps to 34208.36% in 2025.
- The last three EBT Margin figures came in at 34208.36% (Q4 2025), 26.21% (Q3 2025), and 87612.52% (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Evotec SE | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34,208.36% |
| Sep 30, 2025 | -26.21% |
| Dec 31, 2024 | -87,612.52% |
| Sep 30, 2024 | -25.35% |
| Dec 31, 2023 | -13,882.89% |
| Sep 30, 2023 | 15.24% |
| Jun 30, 2023 | -12.00% |
| Dec 31, 2022 | -30,169.50% |
| Sep 30, 2022 | 24.94% |
| Jun 30, 2022 | -14.13% |
| Mar 31, 2022 | -41.74% |
| Dec 31, 2021 | 54,929.35% |
| Sep 30, 2021 | 87.93% |
| Jun 30, 2021 | 43.40% |
| Mar 31, 2021 | 40.91% |
| Dec 31, 2020 | 5,154,605.09% |